ClinicalTrials.gg
Active, not recruitingNCT04487080MARIPOSAUpdated Nov 4, 2026Results posted

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase 3 interventional study of Amivantamab and Osimertinib in Carcinoma, Non-Small-Cell Lung, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 269 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Sep 28, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,074
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 14 under way, 3 of them phase 3. amivantamab · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 15
1,074 · median 80
Started
2020
the only one that year
Phase 3
3 of 15
none open now
Primary completion
2023-08
later than 1 of 13 live
Registered
3rd of 15
by date
Lead sponsor
8 of 15
Janssen Research & Development, LLC

Among the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is the only one that started in 2020, is one of 3 in phase 3, reaches primary completion later than 1 of the 13 other live ones, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About amivantamab

amivantamab: first FDA approval 2021 (RYBREVANT), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have newly diagnosed or cytologically confirmed, locally advanced or non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation
  • The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care
  • Mandatory submission of unstained tissue from tumor (in a quantity sufficient to allow for central analysis of EGFR mutation status and blood (for circulating tumor deoxyribonucleic acid [ctDNA], digital droplet polymerase chain reaction [ddPCR], and pharmacogenomic analysis)
  • Any toxicities from prior anticancer therapy must have resolved to (CTCAE) Grade 1 or baseline level
  • Participant must have at least 1 , according to (RECIST) v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic and be acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy

Exclusion criteria

Exclusion Criteria:

  • Participant has received any prior systemic treatment at any time for locally advanced Stage III or Stage IV disease ( or neoadjuvant therapy for Stage I or II disease is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease)
  • Participant has an active or past medical history of
  • Participant with untreated spinal cord compression. A participant that has been definitively treated with surgery or radiation and has a stable neurological status for at least 2 weeks prior to randomization is eligible provided they are off treatment or receiving low-dose corticosteroid treatment less than or equal to (\<=) 10 milligrams per day (mg/day) prednisone or equivalent
  • Participant has an active or past medical history of interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis
  • Participant has known allergy, , or intolerance to the used in formulation of amivantamab, lazertinib, or osimertinib, or any to the use of osimertinib
  • Participant has symptomatic . A participant with asymptomatic or previously treated and stable brain metastases may participate in this study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,074 participants (actual)

Study arms

  • Experimental
    Treatment Arm A (Open-label): Amivantamab and Lazertinib

    Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (\<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (\>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80\*3) orally once daily.

    Drug: Amivantamab · Drug: Lazertinib

  • Active comparator
    Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib

    Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80\*3) orally once daily.

    Drug: Osimertinib · Drug: Placebo

  • Experimental
    Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib

    Participants will receive lazertinib 240 mg (80\*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.

    Drug: Lazertinib · Drug: Placebo

Interventions

  • Participants will receive amivantamab intravenously.

    Also known as: JNJ-61186372

  • Participants will receive osimertinib capsules orally.

  • Participants will receive lazertinib tablets orally.

    Also known as: JNJ-73841937 and YH-25448

  • DrugPlacebo

    Participants will receive matching placebo orally.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

    PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) the absence of progression, whichever came first. Disease progression was defined using RECIST 1.1 as a 20 percent (%) increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 millimeters (mL). Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment.

    Time frame: From randomization to either disease progression or death whichever occurs first (up to 32.8 months)

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.

    Time frame: Approximately 60 months (time from the date of randomization until the date of death due to any cause)

  2. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve either a complete response (CR) or partial response (PR) as defined by BICR using RECIST v1.1 criteria.

    Time frame: Approximately 32.8 months

  3. Duration of Response (DOR)

    DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST v1.1 criteria.

    Time frame: Approximately 32.8 months

  4. Progression-Free Survival After First Subsequent Therapy (PFS2)

    The PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.

    Time frame: Approximately 60 months

  5. Time to Symptomatic Progression (TTSP)

    TTSP is defined as the time from randomization to documentation in the electronic case report form (eCRF) of any of the following (whichever occurs earlier): onset of new symptoms or symptom worsening that is considered by the investigator to be related to lung cancer and requires either a change in anticancer treatment and/or clinical intervention to manage symptoms.

    Time frame: Approximately 60 months

  6. Intracranial PFS

    Intracranial PFS is defined as the time from randomization until the date of objective intracranial disease progression or death, whichever comes first, based on BICR using RECIST v1.1.

    Time frame: Approximately 60 months

  7. Incidence and Severity of Adverse Events (AEs)

    Incidence and severity of treatment emergent adverse events (TEAEs) will be reported. Any adverse event occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or until the start of subsequent anticancer therapy (if earlier), is considered to be treatment emergent.

    Time frame: Approximately 60 months

  8. Number of Participants With Clinical Laboratory Abnormalities

    Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation, and urine samples) will be reported.

    Time frame: Approximately 60 months

  9. Number of Participants With Vital Signs Abnormalities

    Number of participants with vital signs abnormalities (temperature, heart rate, respiratory rate, oxygen saturation, blood pressure) will be reported.

    Time frame: Approximately 60 months

  10. Number of Participants With Physical Examination Abnormalities

    Number of participants with physical examination abnormalities will be reported.

    Time frame: Approximately 60 months

  11. Serum Concentration of Amivantamab

    Serum samples will be analyzed to determine concentrations of Amivantamab.

    Time frame: Approximately 60 months

  12. Plasma Concentration of Lazertinib

    Plasma samples will be analyzed to determine concentrations of Lazertinib.

    Time frame: Approximately 60 months

  13. Number of Participants With Anti-Amivantamab Antibodies

    Number of participants with antibodies to amivantamab will be reported.

    Time frame: Approximately 60 months

  14. Change From Baseline in Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NCSLC-SAQ)

    The NSCLC-SAQ contains 7 items that assess cough, pain, dyspnea, fatigue, and poor appetite over a 7-day recall period. Each multi-item scale and individual item will be summarized using count and percent by visit.

    Time frame: Baseline up to approximately 60 months

  15. Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)

    EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

    Time frame: Baseline up to approximately 60 months

07

Results

Posted Oct 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneExperimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib
Started429429216
Treated421428213
Completed9411354
Not completed335316162
Withdrew: Withdrawal by subject191813
Withdrew: Lost to follow-up310
Withdrew: Ongoing313297149

Outcome measures

PrimaryProgression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) the absence of progression, whichever came first. Disease progression was defined using RECIST 1.1 as a 20 percent (%) increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 millimeters (mL). Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment.

Time frame:
From randomization to either disease progression or death whichever occurs first (up to 32.8 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
MonthsExperimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)23.72 (19.12 to 27.66)16.59 (14.78 to 18.46)18.46 (14.75 to 20.11)
Statistical analysis
  • Experimental: Arm A (Open-label): Amivantamab + Lazertinib vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.70 · 95% CI 0.58 to 0.85HR and its 95% CI was estimated based on a stratified Cox's regression model with treatment as the sole explanatory variable.
SecondaryOverall Survival (OS)

Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.

Time frame:
Approximately 60 months (time from the date of randomization until the date of death due to any cause)

Results for this outcome have not been posted.

SecondaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants who achieve either a complete response (CR) or partial response (PR) as defined by BICR using RECIST v1.1 criteria.

Time frame:
Approximately 32.8 months

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR)

DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST v1.1 criteria.

Time frame:
Approximately 32.8 months

Results for this outcome have not been posted.

SecondaryProgression-Free Survival After First Subsequent Therapy (PFS2)

The PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryTime to Symptomatic Progression (TTSP)

TTSP is defined as the time from randomization to documentation in the electronic case report form (eCRF) of any of the following (whichever occurs earlier): onset of new symptoms or symptom worsening that is considered by the investigator to be related to lung cancer and requires either a change in anticancer treatment and/or clinical intervention to manage symptoms.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryIntracranial PFS

Intracranial PFS is defined as the time from randomization until the date of objective intracranial disease progression or death, whichever comes first, based on BICR using RECIST v1.1.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryIncidence and Severity of Adverse Events (AEs)

Incidence and severity of treatment emergent adverse events (TEAEs) will be reported. Any adverse event occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or until the start of subsequent anticancer therapy (if earlier), is considered to be treatment emergent.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinical Laboratory Abnormalities

Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation, and urine samples) will be reported.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Vital Signs Abnormalities

Number of participants with vital signs abnormalities (temperature, heart rate, respiratory rate, oxygen saturation, blood pressure) will be reported.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Physical Examination Abnormalities

Number of participants with physical examination abnormalities will be reported.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondarySerum Concentration of Amivantamab

Serum samples will be analyzed to determine concentrations of Amivantamab.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryPlasma Concentration of Lazertinib

Plasma samples will be analyzed to determine concentrations of Lazertinib.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti-Amivantamab Antibodies

Number of participants with antibodies to amivantamab will be reported.

Time frame:
Approximately 60 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NCSLC-SAQ)

The NSCLC-SAQ contains 7 items that assess cough, pain, dyspnea, fatigue, and poor appetite over a 7-day recall period. Each multi-item scale and individual item will be summarized using count and percent by visit.

Time frame:
Baseline up to approximately 60 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)

EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

Time frame:
Baseline up to approximately 60 months

Results for this outcome have not been posted.

Adverse events

Collected over From baseline (Day 1 of Cycle 1) up to 32.8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Arm A (Open-label): Amivantamab + Lazertinib96/421 (22.8%)205/421 (48.7%)419/421 (99.5%)
Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib116/428 (27.1%)143/428 (33.4%)409/428 (95.6%)
Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib56/213 (26.3%)75/213 (35.2%)210/213 (98.6%)
Most frequent serious events
Showing 10 of 253
Most frequent serious events
EventExperimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders26/42110/4288/213
PneumoniaInfections and infestations17/42121/4287/213
Pleural EffusionRespiratory, thoracic and mediastinal disorders9/42117/4283/213
Deep Vein ThrombosisVascular disorders12/4212/4281/213
DyspnoeaRespiratory, thoracic and mediastinal disorders4/42111/4282/213
Covid-19Infections and infestations10/42110/4283/213
Infusion Related ReactionInjury, poisoning and procedural complications9/4210/4280/213
Alanine Aminotransferase IncreasedInvestigations8/4216/4284/213
Pericardial EffusionCardiac disorders4/4215/4284/213
Aspartate Aminotransferase IncreasedInvestigations1/4214/4284/213
Most frequent other events
Showing 10 of 75
Most frequent other events
EventExperimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib
ParonychiaInfections and infestations288/421121/42861/213
Infusion Related ReactionInjury, poisoning and procedural complications261/4210/4280/213
RashSkin and subcutaneous tissue disorders260/421131/42895/213
HypoalbuminaemiaMetabolism and nutrition disorders204/42126/42817/213
DiarrhoeaGastrointestinal disorders123/421189/42868/213
Alanine Aminotransferase IncreasedInvestigations152/42155/42847/213
Oedema PeripheralGeneral disorders150/42124/42824/213
Dermatitis AcneiformSkin and subcutaneous tissue disorders122/42155/42845/213
ConstipationGastrointestinal disorders122/42155/42836/213
StomatitisGastrointestinal disorders122/42190/42838/213

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching OsimertinibTotal
Mean62.7 ± 10.6361.9 ± 11.5261.3 ± 10.6962.1 ± 11.01
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching OsimertinibTotal
Female275251136662
Male15417880412
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching OsimertinibTotal
Hispanic or Latino564524125
Not Hispanic or Latino371382190943
Unknown or Not Reported2226
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching OsimertinibTotal
American Indian or Alaska Native77418
Asian250251128629
Native Hawaiian or Other Pacific Islander1102
Black or African American43411
White16416579408
More than one race1102
Unknown or Not Reported2114
Region of Enrollment
Region of Enrollment(Participants)Experimental: Arm A (Open-label): Amivantamab + LazertinibActive Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching LazertinibExperimental: Arm C (Double-blind): Lazertinib+Placebo Matching OsimertinibTotal
ARGENTINA811625
AUSTRALIA57113
BELGIUM2417
BRAZIL3822969
CANADA0022
CHINA817943203
FRANCE1211629
GERMANY2529
HUNGARY2013
INDIA616325
ISRAEL3328
ITALY118524
JAPAN29321778
MALAYSIA27231060
MEXICO1214531
NETHERLANDS1203
POLAND76013
PORTUGAL4228
RUSSIAN FEDERATION1715840
SOUTH KOREA636833164
SPAIN26331574
TAIWAN24151352
THAILAND159529
TURKEY1521440
UKRAINE10111031
UNITED KINGDOM27211
UNITED STATES751123
08

Study locations

269 sites

Showing the first 100 of 269 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yang JC, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourao Dias J, Besse B, Passaro A, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vazquez Limon JC, Alves S, Stroyakovskiy D, Peregudova M, Sendur MAN, Yazici O, Califano R, Gutierrez Calderon V, de Marinis F, Kim SW, Gadgeel SM, Owen S, Xie J, Sun T, Mehta J, Venkatasubramanian R, Ennis M, Fennema E, Daksh M, Roshak A, Man J, Knoblauch RE, Bauml JM, Baig M, Shah S, Sethi S, Cho BC; MARIPOSA Investigators. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Oct 30;393(17):1681-1693. doi: 10.1056/NEJMoa2503001. Epub 2025 Sep 7. PubMed 40923797 ↗
  • Lee SH, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Dias JM, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Chih-Hsin Yang J, Besse B, Thomas M, Shah S, Baig M, Curtin JC, Zhang J, Xie J, Sun T, Sethi S, Wang M, Fennema E, Daksh M, Ennis M, Bauml JM, Cho BC. Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA. J Thorac Oncol. 2025 Nov;20(11):1655-1668. doi: 10.1016/j.jtho.2025.06.030. Epub 2025 Jul 3. PubMed 40617394 ↗
  • Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourao Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vazquez Limon JC, Alves S, Stroyakovskiy D, Peregudova M, Sendur MAN, Yazici O, Califano R, Gutierrez Calderon V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26. PubMed 38924756 ↗
  • Cho BC, Felip E, Hayashi H, Thomas M, Lu S, Besse B, Sun T, Martinez M, Sethi SN, Shreeve SM, Spira AI. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022 Feb;18(6):639-647. doi: 10.2217/fon-2021-0923. Epub 2021 Dec 16. PubMed 34911336 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Aug 2023, 34 months.

Results were first posted in Oct 2024, 1 year 1 month after primary completion. A results delay was requested in Aug 2024.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 34 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2020
First posted
Jul 27, 2020
StartActual
Sep 30, 2020
Primary completionActual
Aug 11, 2023
CompletionEst.
Feb 16, 2028
Results delay requested
Aug 8, 2024
Results first posted
Oct 9, 2024
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Moscow City Oncology Hospital No 62 · Moscow, Russia
Show 1 removed
  • Moscow City Oncology Hospital № 62 · Moscow, Russia
Sep 28, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 28, 2026
    1 site added, 1 site removed
    Show site
    • Moscow City Oncology Hospital No 62 · Moscow, Russia
    Show 1 removed
    • Moscow City Oncology Hospital № 62 · Moscow, Russia
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04487080
Responsible party
Sponsor
First posted
Jul 27, 2020
Start date
Sep 30, 2020
Primary completion
Aug 11, 2023
Completion
Feb 16, 2028 (estimated)
Results posted
Oct 9, 2024
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amivantamab · Lazertinib

Start the discussion